Online citations, reference lists, and bibliographies.
← Back to Search

Randomized Phase II Trial Of The Efficacy And Safety Of Trastuzumab Combined With Docetaxel In Patients With Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Administered As First-line Treatment: The M77001 Study Group.

M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Antón, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, M. Green, C. Ward, K. Mayne, Jean-Marc Extra
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
PURPOSE This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). PATIENTS AND METHODS Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. RESULTS A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. CONCLUSION Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
This paper references
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
C. Vogel (2002)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)
T. Tabei (2004)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Weekly docetaxel and trastuzumab for her-2-overexpressing metastatic breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study
S. Takao (2004)
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
N. Cook-Bruns (2001)
Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials
J. Baselga (2001)
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Joshua P Raff (2004)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
F. Esteva (2002)
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
H. Burstein (2001)
The biology of erbB-2/neu/HER-2 and its role in cancer.
N. E. Hynes (1994)
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
H. Meden (2001)
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
K. L. Tedesco (2004)
464 Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer
B. Bauer-Kosińska (2003)
Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer: A Pilot Phase II Study
F. Montemurro (2003)
Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)
J. Baselga (2004)
Taxanes in the treatment of advanced breast cancer
L. Krasińska (2003)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
M. Pegram (2004)
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
M. Jahanzeb (2002)
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
A. Seidman (2001)
Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease.
A. Buzdar (2004)
Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy
B. El-Rayes (2004)
Fecal occult blood test for colorectal cancer screening.
H. Strul (2002)

This paper is referenced by
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer
A. Rodallec (2018)
A Case of Salivary Duct Carcinoma in the Submandibular Gland Treated Long-term with a Combination of Trastuzumab and Docetaxel
Saki Yabuuchi (2017)
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
S. Swain (2014)
Benefits of investment into modern medicines in Central–Eastern European countries
A. Inotai (2014)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
S. Tolaney (2020)
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
A. Coveler (2008)
HER2 and TP53 in human breast cancer : Studies of methods and prognostic value
J. Bergqvist (2006)
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
H. Lane (2006)
How to treat male breast cancer.
Czene Kamila (2007)
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
Search for the Holy Grail: evolving targeted therapies in breast cancer
F. Boyle (2008)
Capecitabine and docetaxel in the treatment of metastatic breast cancer: combination, sequence or single agent?
D. Miles (2008)
HER-2 positive breast cancer and trastuzumab: lessons learnt by heart
K. Outhoff (2009)
Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
N. S. Wong (2009)
Sophie Gouérant (2012)
Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications
J. R. Guastalla (2012)
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
S. Ohno (2011)
How to maximize the efficacy of taxanes in breast cancer.
M. Tubiana-Hulin (2005)
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
J. Reis-Filho (2005)
The burden of scientific progress: Growing inequalities in the delivery of cancer care
M. Mano (2006)
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
A. Sapino (2007)
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
S. Gori (2012)
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.
J. Bergqvist (2007)
Metastatic breast cancer : prolongation of survival in routine care is restricted to hormone-receptor-and Her 2-positive tumors
R. Weide (2014)
Difference in physiological parameters following an exercise intervention in breast cancer survivors on a single chemotherapy drug versus combination chemotherapy drugs
Micah John Foster (2010)
Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER 2-positive Metastatic Breast Cancer Patients
Zhen-Li Zhu (2014)
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease
P. Papaldo (2006)
Development and characterization of models of resistance to T-DM1
Juliette Sauveur (2016)
Which Patients with Estrogen Receptor-Positive Early Breast Cancer Should Be Treated with Adjuvant Chemotherapy?
Vincenzo Emanuele Chiuri (2009)
Jumping higher: is it still possible? The ALTTO trial challenge
Gianluca Tomasello (2008)
Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations
X. Pivot (2015)
Immunity & Ageing the Management of Cancer in the Elderly: Targeted Therapies in Oncology Introduction: the Ageing and Cancer Interface
Biagio Agostara ()
See more
Semantic Scholar Logo Some data provided by SemanticScholar